Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...
1d
Edwards maintained its 2025 financial guidance, targeting total company sales of $5.6 billion to $6 billion, with TAVR sales of $4.1 billion to $4.4 billion, TMTT sales of $500 million to $530 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback